Regeneron targets almost 50 patents in suit against Sandoz

Regeneron accused the Swiss pharma company of infringing a slew of patents related to Eylea and violating the BPCIA | Suit alleges that Sandoz failed to provide critical information during the approval process for its newly FDA-approved biosimilar | Sandoz “forced” Regeneron to guess which patents might be infringed.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks

12 March 2026 The event unpacked how technology, litigation trends, and global events are adding complexity while also offering benefits for legal teams under pressure to reduce costs.

Americas

Astellas blocks generic version of key urology drug until 2030

12 March 2026 The pharma company has successfully enforced its patents against Ascent’s proposed mirabegron copy, shortly after inking licensing deals elsewhere over the medication.

Americas

Novo ends Hims & Hers dispute with deal for blockbuster weight-loss drugs

10 March 2026 The telehealth platform’s shares jumped more than 40% after the news that it will sell Ozempic and Wegovy—and no longer faces a lawsuit from the Danish pharma giant.

More features

Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks

Astellas blocks generic version of key urology drug until 2030

Orrick adds specialist licensing partner in Silicon Valley

GSK inks licensing deal for liver disease drug

Arnold & Porter adds tech litigator in San Francisco

Novo ends Hims & Hers dispute with deal for blockbuster weight-loss drugs

UKIPO extends funding for specialist IP crime unit as counterfeit risks grow

Medtech Magnolia fails to revive $2.1m verdict at Fed Circ

Regeneron targets almost 50 patents in suit against Sandoz

More on this story

Editor's picks

Editor's picks

More features